SEC Filing Summary: AntriaBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AntriaBio, Inc. on June 3, 2016, covering events occurring on May 31, 2016. The filing details the completion of an initial close of a private placement transaction with accredited investors under Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D.
Key Financial Metrics
The filing reports the following capital raise metrics:
- Gross Cash Proceeds: $3.3 million (excluding placement agent compensation, transaction costs, fees, and expenses).
- Units Issued: 2,967,935 units (comprising Class A and Class B Units).
- Unit Price: $1.10 per unit.
- Warrant Terms: Warrants exercisable for five years at $1.65 per share.
The filing does not provide data on revenue, profit, operating cash flow, margins, existing debt, or liquidity positions as of the reporting date.
Material Changes
The primary material change is the increase in equity capital and the issuance of unregistered securities. The company entered into purchase agreements with accredited investors, resulting in the issuance of common stock and warrants. No comparative financial data or changes versus prior periods are disclosed in this specific filing.
Outlook, Risks, and Contingencies
Registration Rights: The company agreed to file a registration statement covering the issued shares and warrants within 90 days following the close of the private placement.
Regulatory Status: The securities offered have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption. The filing explicitly states it does not constitute an offer to sell securities.
Unusual Items: The transaction involved two classes of units. Class B Units, which included one full warrant per unit (versus one-half for Class A), were reserved for investors who had previously invested in AntriaBio's private placements and invested a minimum of $50,000 in this transaction.
Investor Verification Checklist
- Verify the final total proceeds after deducting placement agent fees and transaction costs.
- Confirm the filing of the registration statement within the 90-day window post-close.
- Review the company's latest 10-K or 10-Q for current liquidity and debt levels, as this 8-K does not contain balance sheet data.
- Assess the dilution impact of the 2,967,935 new shares and associated warrants on existing shareholders.